Drugmaker begins filing products from India for the Chinese market
Aurobindo Pharma Ltd has commenced filing products in China from India and appears to be bullish on business prospects, going forward, notwithstanding recent tension in bilateral relations between the two nations.
The company has already starting filing products from India for the Chinese market, according to its Managing Director, N Govindarajan.
He was responding to a question on whether the present geopolitical realities between India and China had any impact on the business plans of the Hyderabad-based company in China, in the recent earnings call.
The over $3-billion revenue company is making investments in China. “The construction of our oral formulation manufacturing facility is going on and we expect to take the exhibit batches by the second half of FY2021,’’ Govindarajan said.
Though the products from the Chinese plant may be used for Europe and the US to an extent for a period of time, the drugmaker plans to use it only for the China market after a certain period.
The company has two plants in China — an oral medicine plant and a joint venture.
Aurobindo is also looking at its private business in addition to its joint venture business in China, which it had signed one-and-a-half years back.
It had witnessed certain price correction in terms of the set of products in the tender business. “We will get more clarity as we get closer to the launch. But we are not restricting ourselves only for tender business we will also look at the private business as well as we progress,’’ the executive said.
In the wake of some changes in regulation in China, there is a preference for FDA approved product and FDA inspected facility in China.
“The pricing in the other segments other than tender is also attractive for us to move ahead. But in terms of specifics, we will have more clarity as we go closer to the filing and launch,’’ Govindarajan added.
Thank you for being a loyal user of Portfolio.
Portfolio will be a paid section hereon.
Please Subscribe to get access to one of our early bird packs.
Or click on Free Trial to get 14 days free trial.
What You'll Get
-
Web + Mobile
Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.
-
Exclusive Portfolio and Investment Advice, Banking, Lifestyle and Specials
Get diverse set of perspectives from our trusted experts on Portfolio, Banking, Economy, Environment and others.
-
Ad free experience
Experience cleaner site with zero ads and faster load times.
-
Personalised dashboard
Customize your preference and get a personalized recommendation of stories based on your interest.
Published on
June 22, 2020
A letter from the Editor
Dear Readers,
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.
Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.
In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.
We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism
